ProCE Banner Activity

Outcomes of CLL Patients Treated With Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation

Slideset Download
Conference Coverage
Alternate kinase inhibitor therapy following ibrutinib or idelalisib discontinuation can be efficacious.

Released: December 12, 2015

Expiration: December 10, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen